FDA grants orphan drug status to Merck's pembrolizumab for neuroendocrine prostate cancer

it.investing.com (Italian)

The FDA granted orphan drug status to Merck's pembrolizumab for neuroendocrine prostate cancer. This designation provides incentives for developing treatments for rare diseases, offering seven years of market exclusivity if approved. Pembrolizumab, known as Keytruda, is currently being studied in clinical trials for this specific cancer indication.


With a significance score of 2.6, this news ranks in the top 17% of today's 33740 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


FDA grants orphan drug status to Merck's pembrolizumab for neuroendocrine prostate cancer | News Minimalist